anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Hepatic fibrosis is a major public health problem that endangers human wellbeing. In recent years, a number of studies have revealed the important impact of metabolic reprogramming on the occurrence and development of hepatic fibrosis. Among them, the Warburg effect, as an intracellular glucose metabolism reprogramming, can promote the occurrence and development of hepatic fibrosis by promoting the activation of hepatic stellate cells (HSCs) and inducing the polarization of liver macrophages (KC). Understanding the Warburg effect and its important role in the progression of hepatic fibrosis will assist in developing new strategies for the prevention and treatment of hepatic fibrosis. This review focuses on the Warburg effect and the specific mechanism by which it affects the progression of hepatic fibrosis by regulating HSCs activation and KC polarization. In addition, we also summarize and discuss the related experimental drugs and their mechanisms that inhibit the Warburg effect by targeting key proteins of glycolysis in order to improve hepatic fibrosis in the hope of providing more effective strategies for the clinical treatment of hepatic fibrosis.
PURPOSE:To easily measure a TSH-beta subunit by using a monoclonal antibody as an antibody in the stage of quantitatively determining the TSH-beta subunit. CONSTITUTION:The monoclonal having specificness only to the TSH-beta subunit is used without substantially labeling the TSH as the antibody in the stage of quantitatively determining the TSH-beta subunit in blood or bodily fluid by the antigen-antibody reaction. This antibody is obtd. by investigating the specificness of the monoclonal antibody generative hybridomas obtd. by the confluence of the spleen cells of the mouse immunized by the TSH or TSH-beta subunit and mouse myeloma cells, selecting hybridoma which generates the monoclonal antibody having the specificness only to the beta-subunit among said hybridomas and propagating the same in an artificial culture or the abdominal cavity of the mouse. The measurement of the TSH-beta subunit by an ordinary immunological measurement method is made easy by using such monoclonal antibody.
The invention relates to a traditional Chinese medicinal formula for treating acute enteritis by oral administration. Acute enteritis often occurs in hot summer and autumn. In Western medicine, anti-inflammatory and antibacterial drugs are used for treatment of acute enteritis, but sometimes, intestinal beneficial bacterial colonies are severely killed, causing intestinal dysfunction and conversion from acute enteritis to chronic enteritis. The traditional Chinese medicinal preparation has effects of removing dampness by diuresis, clearing away heat, and invigorating spleen and stomach, and has good drug effect, low toxic and adverse effects, no drug resistance and the like. The traditional Chinese medicinal preparation comprises the following ingredients in parts by weight: 8-12 parts of Scutellaria baicalensis, 8-12 parts of Rhizoma Atractylodis (Atractylodes lancea and/or Atractylodes chinensis), 6-14 parts of Radix Puerariae (Pueraria lobata and/or Pueraria thomsonii), 5-15 parts of Nelumbo nucifera leaf, 8-12 parts of Aucklandia lappa, Pogostemon cablin, 10-20 parts of parched Dolichos lablab seed, 2-4 parts of Rhizoma Coptidis, 8-10 parts of Magnolia officinalis, 2-4 parts of processed Radix Glycyrrhizae, 9-15 parts of Angelica dahurica, 8-12 parts of Alisma orientalis, 10-20 parts of Perilla frutescens leaf, and 12-18 parts of parched Massa Medicata Fermentata. The traditional Chinese medicinal preparation has effects of clearing the bowels, relieving diarrhea, and relieving exterior and interior syndromes, and has good therapeutic effect on acute enteritis, bacillary dysentery, ileotyphus, gastrointestinal type cold and other diseases due to non-relief of exterior syndrome and intense heat. The traditional Chinese medicinal preparation takes action after 2 days of administration, and patients are clinically recovered after 3-4 days.
A system and method are provided for simulating a Laser Induced Optical Breakdown (LIOB) protocol to establish a surgical LIOB treatment for a patient. In the system, a library of finite element models characterizing various visual defects in corneas are programmed into a computer. Further, a library of nomograms indicating specific LIOB protocols for correcting respective visual defects are programmed into the computer. As a result, a model and a corresponding nomogram may be selected in view of a patient's diagnostic information. Further, the selected model may be individualized with the diagnostic information to more precisely characterize the patient's visual defects. Thereafter, the computer simulates the indicated LIOB protocol on the individualized model in order to achieve a desired corneal configuration. When the desired corneal configuration is achieved, the final treatment plan may be determined.
Spousal bereaved individuals (age 25-85) in the Central Denmark Region identified through a data extraction of the Danish Civil Registration System (CPR) every sixth week over a period of one year. The group will complete a survey at respectively 2 (T1), 6 (T2), 11 (T3), 18 (T4), and 26 (T5) months post-loss as well as 3, 4, 5 and 6 years post loss.
PURPOSE:To readily remove a free and contaminating coloring matter ligand by purifying an antigenic protein according to triazine coloring matter affinity chromatography and then subjecting the resultant purified antigenic protein to hydrophobic chromatography. CONSTITUTION:A gel of a chromatographic material prepared by covalently bonding a triazine coloring matter to a carrier having a high physical strength is added to an antigenic solution containing an antigenic protein (e.g. pertussis toxin or fibrous hemagglutinin) having specific affinity for the triazine coloring matter and nearly the total amount of the antigenic protein is adsorbed on the aforementioned chromatographic material, which is then washed to remove nonspecifically adsorbed endotoxins. The adsorbed fractions are subsequently eluted to provide an antigenic solution in a high concentration. The above-mentioned antigenic solution is then added to a hydrophobic column to remove the contaminating coloring matter ligand. Thereby, the coloring matter ligand can be completely removed without using any expensive apparatus, such as an ultracentrifuge, and deterioration in yield due to insolubilization of the antigenic protein can be avoided.
OBJECTIVE: To evaluate a cohort of patients diagnosed with benign ureteroenteric stricture (UES) after radical cystectomy with ileal conduits using a strict predefined definition of strictures. Additionally, we want to illustrate the UES debut, regarding symptoms and clinical findings. UES is a well-known long-term complication after radical cystectomy, affecting up to 20% of all patients. In the literature, different incidence rates are reported. However, these are based on various definitions of strictures.
METHODS: We used strict predefined criteria to evaluate UES incidence including symptoms, timing, diagnostic methods, treatment, and outcome in all patients who underwent radical cystectomy with an ileal conduit between 2012 and 2018 at a single high-volume center.
RESULTS: Of a total of 693 patients who underwent radical cystectomy with ileal conduit, we found 109 patients with 135 UES in total, corresponding to 15.7% of patients (CI: 13.2-18.6) and 10% of all included ureteroenteric anastomosis (CI: 8.5-11.6) after radical cystectomy. Median follow-up was 24months (interquartile range (IQR): 12-31), and postoperatively UES was diagnosed after a median of 6months (IQR: 3-16). A total of 56% was diagnosed with elevated creatinine. Every UES underwent a median of two (IQR: 1-2) treatment attempts and 122 UES were treated successfully.
CONCLUSION: Benign UES is a significant cause of morbidity following radical cystectomy. Our findings contribute to the knowledge of timing, incidence, and recommended treatment of strictures. We argue the importance of establishing a clear gold standard when defining UES to ensure accurate reporting in future research.
1,217,388. 9,10-Ethanoanthracenes. SOC. INDUSTRIELLE POUR LA FABRICATION DES ANTIBIOTIQUES. 30 May, 1968 [8 June, 1967; 6 Sept., 1967], No. 25883/68. Heading C2C. The invention comprises compounds of the Formula (I) and their acid addition and quaternary ammonium-salts wherein R represents a hydrogen atom or a C 1-6  alkyl, C 1-6  hydroxyalkyl, C 2-6  alkoxy carbonyl or C 2-6  hydroxy alkoxyalkyl radical or a radical of the formula -X-Ar, wherein X represents a divalent radical derived from a C 1-6  saturated or unsaturated aliphatic hydrocarbon and Ar represents a phenyl radical which may be substituted by one or more halogen atoms and/or one or more C 1-6  alkyl or C 1-6  alkoxy radicals and their preparation by reacting a 9,10-dibromoanthracene with a 1 -R-substituted-piperazine in the presence of a hydrogen bromide-binding alkaline agent and heating the resulting 9-(1-R-aubstituted - piperazin - 4 - yl) anthracene of the Formula (3) with ethylene under a pressure of at least 30 kg./cm.<SP>2</SP> in a solvent and where R represents an C 2-6  alkoxycarbonyl radical, hydrolysing said compound to give a compound of the Formula (I) where R represents a hydrogen atom and, if desired, reacting said compound with a halide of the formula Hal-R 1 , where R 1  is the same as R but does not represent a hydrogen atom or an alkoxycarbonyl group and Hal represents a chlorine, bromine or iodine atom and, if desired, converting any resulting compound of the Formula (I) into an acid addition or quaternary ammonium salt thereof. 9 - (1 - R 2  - substituted - piperazin - 1 - yl) anthracenes of the Formula (III) may also be prepared by reacting a 9-bromoanthracene with 1 - R 2  - substituted - piperazin - 4 - yl - lithiums where R 2  has the same meaning as R except that it does not represent a hydrogen atom or a hydroxyalkyl, alkoxycarbonyl or hydroxyalkoxyalkyl radical. Therapeutic compositions with antihistaninic and antianaphylactic properties, for oral, parenteral or topical administration, comprise the compounds of the invention with a carrier.
INTRODUCTION: Epilepsy is a common neurological disorder that presents with challenging mechanisms and treatment strategies. This study investigated the neuroprotective effects of quinpirole on lithium chloride pilocarpine-induced epileptic rats and explored its potential mechanisms.
METHODS: Lithium chloride pilocarpine was used to induce an epileptic model in rats, and the effects of quinpirole on seizure symptoms and cognitive function were evaluated. The Racine scoring method, electroencephalography, and Morris water maze test were used to assess seizure severity and learning and memory functions in rats in the epileptic group. Additionally, immunohistochemistry and Western blot techniques were used to analyze the protein expression levels and morphological changes in glutamate receptor 2 (GluR2; GRIA2), BAX, and BCL2 in the hippocampi of rats in the epileptic group.
RESULTS: First, it was confirmed that the symptoms in rats in the epileptic group were consistent with features of epilepsy. Furthermore, these rats demonstrated decreased learning and memory function in the Morris water maze test. Additionally, gene and protein levels of GluR2 in the hippocampi of rats in the epileptic group were significantly reduced. Quinpirole treatment significantly delayed seizure onset and decreased the mortality rate after the induction of a seizure. Furthermore, electroencephalography showed a significant decrease in the frequency of the spike waves. In the Morris water maze test, rats from the quinpirole treatment group demonstrated a shorter latency period to reach the platform and an increased number of crossings through the target quadrant. Network pharmacology analysis revealed a close association between quinpirole and GluR2 as well as its involvement in the cAMP signaling pathway, cocaine addiction, and dopaminergic synapses. Furthermore, immunohistochemistry and Western blot analysis showed that quinpirole treatment resulted in a denser arrangement and a more regular morphology of the granule cells in the hippocampi of rats in the epileptic group. Additionally, quinpirole treatment decreased the protein expression of BAX and increased the protein expression of BCL2.
CONCLUSION: The current study demonstrated that quinpirole exerted neuroprotective effects in the epileptic rat model induced by lithium chloride pilocarpine. Additionally, it was found that the treatment not only alleviated the rats' seizure symptoms, but also improved their learning and memory abilities. This improvement was linked to the modulation of protein expression levels of GLUR2, BAX, and BCL2. These findings provided clues that would be important for further investigation of the therapeutic potential of quinpirole and its underlying mechanisms for epilepsy treatment.
The historical use of the term non-alcoholic fatty liver disease (NAFLD) in obese/overweight children has been controversial as to the appropriateness of this terminology in children, and lately, in adults too. Newer game-changer terminology, metabolic (dysfunction)-associated fatty liver disease (MAFLD), for this condition signifies a positive step forward that addresses the limitations of the previous definition for both adults and children. The prevalence of MAFLD has surged in tandem with the global rise in obesity rates, establishing itself as a predominant cause of chronic liver disease in both adult and pediatric populations. The adoption of the recently proposed nomenclature reflects a more encompassing comprehension of the disease and its etiology compared to its predecessor, NAFLD. Notably, the revised terminology facilitates the recognition of MAFLD as an autonomous condition while acknowledging the potential coexistence of other systemic fatty liver disorders. Particularly in children, this includes various paediatric-onset genetic and inherited metabolic disorders, necessitating thorough exclusion, especially in cases where weight loss interventions yield no improvement or in the absence of obesity. MAFLD presents as a multifaceted disorder; evidence suggests its origins lie in a complex interplay of nutritional, genetic, hormonal, and environmental factors. Despite advancements, current non-invasive diagnostic biomarkers exhibit limitations in accuracy, often necessitating imaging and histological evaluations for definitive diagnosis. While dietary and lifestyle modifications stand as cornerstone measures for MAFLD prevention and management, ongoing evaluation of therapeutic agents continues. This article provides an overview of the latest developments and emerging therapies in the realm of paediatric MAFLD.
HOE901-U300 (new insulin glargine 300 units per milliliter \[U/mL\]) subcutaneous (SC) injection once daily in morning for 8 weeks during treatment period A, followed by once daily in evening for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 millimole per liter (mmol/L).
If the combination of atezolizumab and guadecitabine is found to be safe and tolerable in Cohort A1, Cohort A3 will assess the safety and tolerability of the combination in 6 participants with untreated AML, who are older and unfit for induction chemotherapy. All participants will receive atezolizumab (840 mg IV on Days 8 and 22 of every 28-day cycle) administered in combination with guadecitabine (60 mg/m\^2 SC on Days 1-5 of every 28-day cycle). Treatment with both study drugs will continue until loss of clinical benefit except in participants who achieve a CR, CRp, or CRi), evidence of unacceptable toxicity, voluntary withdrawal from the study, study termination, or death, whichever occurs first. Participants who achieve a CR, CRp, or CRi will receive an additional six cycles of the combination as consolidation treatment. Participants will discontinue therapy at the end of consolidation response assessment even if the CR, CRp, or CRi is maintained at that time.
Approximately six (6) subjects will be treated to determine the RP2D. At the designated RP2D, approximately fifteen (15) additional subjects will be treated.
BACKGROUND: Identification of hypoxaemia and hypercapnia is essential for the diagnosis and treatment of acute respiratory failure. While arterial blood gas (ABG) analysis is standard for PO2 and PCO2 measurement, venous blood gas (VBG) analysis is increasingly used as an alternative. Previous systematic reviews established that VBG reporting of PO2 and PCO2 is less accurate, but the impacts on clinical management and patient outcomes are unknown.
AIMS: This study aimed to systematically review available evidence of the clinical impacts of using ABGs or VBGs and examine the arteriovenous difference in blood gas parameters.
METHODS: A comprehensive search of the MEDLINE, Embase and Cochrane Library databases since inception was conducted. Included studies were prospective or cross-sectional studies comparing peripheral ABG to peripheral VBG in adult non-critical care inpatients presenting with respiratory symptoms.
RESULTS: Of 15 119 articles screened, 15 were included. No studies were found that examined clinical impacts resulting from using VBG compared to ABG. Included studies focused on the agreement between ABG and VBG measurements of pH, PO2, PCO2 and HCO3 -. Due to the heterogeneity of the included studies, qualitative evidence synthesis was performed. While the arteriovenous difference in pH and HCO3 - was generally predictable, the difference in PO2 and PCO2 was more significant and less predictable.
CONCLUSIONS: Our study reinforces the notion that VBG is not comparable to ABG for physiological measurements. However, a key revelation from our research is the significant lack of data regarding the clinical implications of using VBG instead of ABG, a common scenario in clinical practice. This highlights a critical knowledge gap.
Disclosed is a method for treatment of neurological and viral diseases and especially to the treatment of heretofore intractable diseases such as Rabies, Myasthenia Gravis, HIV Dementia, Muscular Dystrophy, Multiple Sclerosis and Amyotrophic Lateral Sclerosis through modulation or blockade of the nicotinic acetylcholine receptor. Also disclosed is the treatment composition of matter and methods of making same. Treatment is based on the fact that certain modified alpha-neurotoxins have the ability to attach to or otherwise modulate the nicotinic acetylcholine receptor by blocking attachment or involvement with pathogenic organisms, viruses, or proteins with potentially deleterious functions. The modified alpha-neurotoxins may be derived from various venoms including certain genera of snakes and Conus snails and are prepared by detoxification of the purified neurotoxins or contained in whole venom. The native neurotoxin or venom may be detoxified by controlled oxygenation. A novel high temperature technique is also described. Alternatively, the specific neurotoxin may be generated through cloning or synthetic techniques with mutations or non-native amino acids substituted to reduce the affinity of the resulting neurotoxin for its receptor. The present composition may also be produced from any venom which acts, essentially, as a neurotoxin, as opposed to, essentially, a hematoxin. However, the composition must be derived from venoms which contains alpha-neurotoxins such as obtained from the genus Bungarus.
INTRODUCTION: Aseptic femoral stem loosening is among the most common causes for revision in total hip arthroplasty (THA). We describe a simple clinical test that triggers pain in the proximal femur in patients with a loose stem. A previously described passive rotation test was associated with a poor sensitivity. The resisted torsional stress test (RTST) was used for several years in our hospital, and this is the first description of its reliability.
METHODS: We retrospectively reviewed our database of uncemented stem revisions. Preoperative clinical reports were searched for data on the RTST. A positive RTST was defined as sharp pain felt at the stem level with active internal rotation against a passive external rotation impulse in 90° hip flexion. The definition of stem fixation (fixed vs. loose) was made by readout of the surgery reports.
RESULTS: The RTST was reported in 83 cases and was positive in 32 of the 43 stems, which were found loose intraoperatively and in 9 of the 40 stems, which were well integrated. This leads to an accuracy of classification of 79.5%. The sensitivity was 80% and the specificity was 79.1%. PPV and NPV were 78% and 81%, respectively.
CONCLUSION: The RTST provides a helpful tool in the clinical assessment of femoral stem fixation in THA with good accuracy and should be included in standard follow-up examinations and in the assessment of painful THAs.
* Each single-patient-use HUMATROPE cartridge is designed for use only with the appropriate corresponding HumatroPen®.
    * Reconstitute each cartridge of HUMATROPE using only the diluent syringe that accompanies the cartridge. Do not shake. The reconstituted solution should be clear. 
    * Inspect visually for particulate matter and discoloration. If the resulting solution is cloudy or contains particulate matter do not use. 
    * The somatropin concentrations for the reconstituted HUMATROPE cartridges are as follows in Table 1: 
  * Reconstituted cartridges of HUMATROPE are stable for up to 28 days when refrigerated at 36° to 46°F (2° to 8°C). Do not leave at room temperature more than 30 minutes per day. Avoid freezing the reconstituted cartridge. Protect HUMATROPE from light during storage. 
  * For patients with known hypersensitivity to the diluent supplied with the HUMATROPE cartridge [see Warnings and Precautions (5.6)], do not use HUMATROPE cartridge.
PROBLEM TO BE SOLVED: To obtain a new sulfonamide benzamide derivative having a differentiating effect on a cell and useful as a therapeutic or improving agent as a medicine for malignant tumors, a autoimmune diseases, dermatological diseases and a parasitic infectious diseases. SOLUTION: This differentiation-inducing agent is a sulfonamide benzamide derivative expressed by formula I [X is a direct bond, CH2 , CH2 CH2 , CH=CH, OCH2 on the like.; (n) is 0, 1; A is an aromatic heterocyclic ring containing one or two nitrogen atoms or formula II; R1 is H, a 1-4C alkyl or benzyl; R2 to R6 are each H, a halogen, amino or the like). For example, a compound expressed by formula III. The compound of formula I is obtained e.g. by subjecting a compound expressed by the formula: A-X-SO2 Q (Q is hydroxyl or a halogen) and a compound expressed by formula IV (E is t-butoxycarbonyl, benzyloxycarbony or the like) to a condensation reaction.
PURPOSE: A solid film which is quickly soluble in biological liquid is provided to protect wound of human body by emitting scarring material, disinfectant material, and cosmetic material. CONSTITUTION: A solid film which is quickly soluble in liquid for using alimentary contains 25-60% of alginate, 0.1-20% of micro crystalloid cellulose, and 0.1-25% of vegetable protein. The water has 0.1-0.3 of water activity and thickness is 60-150 um. The soluble time is 10 to 20 seconds. The solid film contains emulsion generating material, emulsifier/texturizer, plasticizer/wetting agent, filmogen, aroma agent, pharmaceutically active product, and cosmetic active product. The emulsifier/texturizer is polyoxyethytlene derivative, natural gum, natural emulsifier, cellulose deriavative and dethylcellulose.